MedTrace Logo

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

NCT00348023 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2007-02-09

No results posted yet for this study

Summary

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%

Sponsors & Collaborators

  • Innovative Medical

    lead INDUSTRY

Principal Investigators

  • Robert Noecker, MD · UPMC Eye Center

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348023 on ClinicalTrials.gov